Literature DB >> 1480774

Is the experience with CHART compatible with experimental data? A new model of repair kinetics and computer simulations.

R Guttenberger1, H D Thames, K K Ang.   

Abstract

A new incomplete repair model is introduced that differs from previous models of this type by not assuming that repair is complete during long intervals, e.g. "overnight" intervals of 12-24 h. The model was used to assess the risk of myelopathy resulting from continuous hyperfractionated accelerated radiotherapy treatment (CHART) in light of recent experimental data on the rat spinal cord. Model calculations employing biexponential repair kinetics showed that CHART treatments might result in a higher myelopathy risk than an equal dose given in conventional 2-Gy fractions if the parameters obtained from the animal data hold. The probability of observing what has been reported for CHART was determined in computer simulations for different variance scenarios. The chance to observe four myelopathies in the 74 cervical cord patients was estimated to range between 25 and 62%, while the probability to see 0 in 68 thoracic cord patients ranged from 48 to 27%. These numbers were derived from reasonable assumptions about the repair kinetics (e.g. 60% of damage repaired with a half-time of 8 h) so that the over-all probability to observe 4/74 and 0/68 was maximized, and depending on the scenario fell in the range 12-17%. Finally, from these simulations a myelopathy risk of approximately 0.3-1.2% is predicted for the currently employed maximal CHART dose to the spinal cord, i.e. 42 Gy. We conclude that the CHART experience is not compatible with the new experimental data (p < 5%). Incomplete repair is unlikely to be the sole reason for the unexpected toxicity of CHART (p < or = 17%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1480774     DOI: 10.1016/0167-8140(92)90248-s

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  [Risks of unfavorable cosmetic and toxicity after percutaneous accelerated partial breast irradiation (APBI). Interim analysis from the Canadian RAPID trial].

Authors:  M D Piroth
Journal:  Strahlenther Onkol       Date:  2013-12       Impact factor: 3.621

2.  [Arrhythmias].

Authors:  Lars Eckardt
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-11       Impact factor: 0.840

3.  Cervical osteoradionecrosis following accelerated fractionation radiation therapy for laryngeal cancer.

Authors:  Mark Zaki; Yiqing Xu; Michael Joiner; Harold Kim; Michael Dominello
Journal:  Pract Radiat Oncol       Date:  2016-03-07

4.  Reports of unexpected late side effects of accelerated partial breast irradiation--radiobiological considerations.

Authors:  Søren M Bentzen; John R Yarnold
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-15       Impact factor: 7.038

Review 5.  Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature.

Authors:  J Lutterbach; J Liegibel; D Koch; A Madlinger; H Frommhold; A Pagenstecher
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.